Bayer Ag · XETR:BAYN
Bayer — Technical Presentation (2025)
10 slides from Bayer's technical presentation, 2025
Slide 1: Efficacy of Finerenone in Heart Failure: Analysis of Heart Rate in FINEARTS-HF
Efficacy Of Finerenone In Patients With Heart Failure And Mildly Reduced Or Preserved Ejection Fraction: A Pre- specified Analysis Of Heart Rate In The Finearts-hf Trial Misato Chimura | University of Glasgow, Glasgow, United Kingdom #AHA25
Slide 2: Disclosures
DISCLOSURES I have received research grants from the Daiwa Foundation and the Japan Research Foundation for Clinical Pharmacology. The FINEARTS-HF trial was sponsored by Bayer AG. 2
Slide 3: Background: Heart Rate in FINEARTS-HF
BACKGROUND: HEART RATE IN FINEARTS-HF • Resting heart rate (HR) is a prognostic factor in HFrEF, where higher HR correlates with higher risk and HR-lowering improves outcomes¹. These findings appear to apply only to sinus rhythm (SR) and not atrial fibrillation (AF)2. However, it is unclear whether
Slide 4: Objective: Heart Rate in FINEARTS-HF
OBJECTIVE: HEART RATE IN FINEARTS-HF The aim of this study was to examine the association between baseline HR and clinical outcomes according to heart rhythm, and to evaluate the effect of finerenone across the HR spectrum in patients with HFmrEF/HFpEF. 4
Slide 5: Trial Design: Heart Rate in FINEARTS-HF
TRIAL DESIGN: HEART RATE IN FINEARTS-HF Key Inclusion Criteria Primary endpoint ・LVEF > 40% Total (first and recurrent) HF events (unplanned ・NYHA functional class II-IV HF hospitalizations or urgent HF visits) and CV ・Elevated natriuretic peptide levels death ・Structural heart disease (LA Enlargeme
Slide 6: Baseline Characteristics: Heart Rate in FINEARTS-HF
Baseline characteristics: HEART RATE IN FINEARTS-HF Sinus Rhythm Atrial Fibrillation HR, <63 bpm HR, 63-72 bpm HR, >72 bpm HR, <71 bpm HR, 71-83 bpm HR, >83 bpm (n = 1197) (n = 1188) (n = 1112) (n = 735) (n = 750) (n = 705) Age (years) 72 ± 9 70 ± 10 69 ± 11 75 ± 9 75 ± 9 73 ± 9 Female – (%) 45 48 4
Slide 7: Clinical Outcome: Heart Rate in FINEARTS-HF
CLINICAL OUTCOME: HEART RATE IN FINEARTS-HF A Primary composite outcome B Total HF events C Cardiovascular death P for interaction < 0.001 P for interaction < 0.001 P for interaction ＝0.04 Heart rate (bpm) Heart rate (bpm) Heart rate (bpm) ■ Sinus rhythm ■ AF 7
Slide 8: Change in Heart Rate: Heart Rate in FINEARTS-HF
CHANGE IN HEART RATE : HEART RATE IN FINEARTS-HF Sinus rhythm Atrial fibrillation Month Month The mean placebo-corrected difference The mean placebo-corrected difference from randomization to 12 months from randomization to 12 months 0.03 (-0.57 to 0.64) bpm p=0.91 -1.35 (-2.29 to -0.41) bpm p=0.005
Slide 9: Treatment Effect: Heart Rate in FINEARTS-HF
TREATMENT EFFECT: HEART RATE IN FINEARTS-HF Sinus rhythm A Primary composite outcome B Total HF events C Cardiovascular death P for interaction=0.96 P for interaction=0.65 P for interaction=0.48 Heart rate (bpm) Heart rate (bpm) Heart rate (bpm) Atrial fibrillation A Primary composite outcome B Tota
Slide 10: Summary and Conclusions: Heart Rate in FINEARTS-HF
SUMMARY AND CONCLUSIONS: HEART RATE IN FINEARTS-HF • In patients with HFpEF/HFmrEF in the FINEARTS-HF trial, higher baseline HR was associated with a higher risk of clinical outcomes among patients in SR, but not in those in AF. • Among patients in SR, there was no significant difference between fin